» Articles » PMID: 39592693

Clinical Imaging Diagnosis of Pulmonary Cryptococcosis with Different Therapeutic Responses

Overview
Journal Sci Rep
Specialty Science
Date 2024 Nov 26
PMID 39592693
Authors
Affiliations
Soon will be listed here.
Abstract

We aimed to differentiate and evaluate the clinical imaging features of pulmonary cryptococcosis with different therapeutic responses. The clinical imaging data of 70 patients with PC (complete response PC 37 cases and incomplete response PC 33 cases) were collected and compared to determine the independent risk factors for different therapeutic responses, and their diagnostic performances were verified by receiver operating characteristic curve analysis. Compared with complete response PC, incomplete response PC was more common with immunosuppression (10.8% vs. 45.5%, P = 0.001), intermediate progress (8.1% vs. 39.4%, P = 0.002), bilateral distribution (21.6% vs. 78.8%, P < 0.001), consolidation-interstitial pattern (10.8% vs. 42.4%, P = 0.003), pleural effusion (0 vs. 27.3%, P = 0.002) and mediastinal lymphadenopathy (0 vs. 24.2%, P = 0.005). Multivariate logistic regression showed that immunosuppression, intermediate progress, and bilateral distribution were independent risk factors, with low to moderate areas under curves (AUC, 0.656-0.786). Their combined performance was good with an AUC of 0.888. The diverse clinical imaging features can reflect the therapeutic response of PC. Immunosuppression, intermediate progress, and bilateral distribution were independent risk factors. Their combination can significantly improve diagnostic effects.

Citing Articles

Lateral flow assay as radiological prognosis factor of pulmonary cryptococcosis: a single center retrospective study in China.

Shi J, Chen J, Ding Q, Qian G, Zhang Z, Song Q Front Cell Infect Microbiol. 2025; 14:1497082.

PMID: 39906214 PMC: 11790446. DOI: 10.3389/fcimb.2024.1497082.

References
1.
Deng H, Zhang J, Li J, Wang D, Pan L, Xue X . Clinical features and radiological characteristics of pulmonary cryptococcosis. J Int Med Res. 2018; 46(7):2687-2695. PMC: 6124262. DOI: 10.1177/0300060518769541. View

2.
Yan Y, Wu Y, Wang Q, Zhu X, Li H, Jiang H . Lesion size as a prognostic factor in the antifungal treatment of pulmonary cryptococcosis: a retrospective study with chest CT pictorial review of 2-year follow up. BMC Infect Dis. 2023; 23(1):153. PMC: 10012437. DOI: 10.1186/s12879-023-08131-0. View

3.
Setianingrum F, Rautemaa-Richardson R, Denning D . Pulmonary cryptococcosis: A review of pathobiology and clinical aspects. Med Mycol. 2018; 57(2):133-150. DOI: 10.1093/mmy/myy086. View

4.
Wang D, Zhang Q, Wen Q, Ding G, Wang Y, Du F . Comparison of CT findings and histopathological characteristics of pulmonary cryptococcosis in immunocompetent and immunocompromised patients. Sci Rep. 2022; 12(1):5712. PMC: 8983692. DOI: 10.1038/s41598-022-09794-6. View

5.
Perfect J, Dismukes W, Dromer F, Goldman D, Graybill J, Hamill R . Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010; 50(3):291-322. PMC: 5826644. DOI: 10.1086/649858. View